Benefits / risks for fibrinolytic therapy in intermediate-risk PE

April 11, 2014
Benefits/Risks for fibrinolytic therapy in intermediate-risk PE

(HealthDay)—A single intravenous bolus of tenecteplase reduces early death and hemodynamic decompensation in normotensive patients with intermediate-risk pulmonary embolism, but increases the risk of major hemorrhage and stroke, according to a study published in the April 10 issue of the New England Journal of Medicine.

Guy Meyer, M.D., from the Hôpital Européen Georges Pompidou in Paris, and colleagues randomized 1,005 normotensive patients with intermediate-risk pulmonary embolism due to right ventricular dysfunction and myocardial injury to tenecteplase plus heparin or placebo plus heparin. A composite of death or hemodynamic decompensation (or collapse) within seven days of randomization marked the primary outcome.

The researchers found that death or hemodynamic decompensation occurred in 2.6 percent of the 506 patients in the tenecteplase group versus 5.6 percent of the 499 patients in the placebo group (odds ratio, 0.44; P = 0.02). Death occurred in the first seven days in six patients in the tenecteplase group and nine patients in the placebo group (P = 0.42). Extracranial bleeding occurred in 32 patients in the tenecteplase group and six patients in the (6.3 versus 1.2 percent; P < 0.001). In the tenecteplase group, 12 patients had a stroke (2.4 percent), of which 10 were hemorrhagic, compared to one patient with in the control group (P = 0.003).

"In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke," the authors write.

The study was funded in part by a grant from Boehringer Ingelheim.

Explore further: Clot-busting drug benefits intermediate-risk patients with pulmonary embolism

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Clot-busting drug benefits intermediate-risk patients with pulmonary embolism

March 12, 2013
The clot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75, according to research presented ...

Hepatic decompensation higher with HIV, HCV co-infection

March 18, 2014
(HealthDay)—Patients co-infected with HIV and hepatitis C virus (HCV) have higher rates of hepatic decompensation than those with HCV monoinfection, according to a study published in the March 18 issue of the Annals of ...

First guidelines for patients with pulmonary hypertension in sickle cell disease

March 18, 2014
Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) physicians have helped create the first set of clinical guidelines for treating patients with pulmonary hypertension in sickle cell disease. Elizabeth ...

Clot-busting drug as effective as angioplasty

March 12, 2013
A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

November 11, 2013
(HealthDay)—Bardoxolone methyl does not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, according to a study published ...

Macitentan cuts morbidity, death in pulmonary arterial HTN

August 29, 2013
(HealthDay)—For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.